Li Qiang, Zhang Liu, Li Zhen, Mu Shulin, Cheng Tan, Tian Faming, Liu Yongqiang
Department of Orthopaedics, Affiliated Hospital of North China Coal Medical College, Tangshan Hebei, 063000, PR China.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Mar;23(3):294-8.
To investigate the effects of xianlinggubao (XLGB) on subchondral bone and articular cartilage in the rat osteoarthritis model induced by anterior cruciate ligament transection (ACLT).
Twenty-four 3-month-old female SD rats were divided randomly into 3 groups (n=8): Sham group (group A), ACLT group (group B) and XLGB group (group C). The osteoarthritis model was made by ACLT in groups B and C, the joint cave was sutured after exposure of ACL in group A. After 4 days, XLGB was given at 250 mg/(kgd) in group C and the equivalent amount of saline was given in groups A and B. After 12 weeks, the gross appearance of femoral condyles was observed, the degree of cartilage degeneration was scored by Mankin scoring system. The immunostaining for MMP-13 was performed to investigate the effect of XLGB on prevention of cartilage matrix loss. The bone mineral density (BMD) measurement and bone histomorphometric analysis were done in subchondral bone of right distal femur and proximal tibia after 12 weeks.
The gross appearance of femoral condyles showed that ulcer in the group C was smaller than that in group B after 12 weeks. The Mankin's scale and IA value for MMP-13 in group C were markedly lower than those in group B (P < 0.05). BMD of the subchondral bone in the group B was significantly lower than those in the groups A and C (P < 0.05). The bone mass in group C were significantly higher than that in group B (P < 0.05).
Oral administration of XLGB (250 mg/kg per day) for 12 weeks could prevent the cartilage degeneration of rats after ACLT, down-regulating MMP-13 and increasing subchondral bone mass might participate in this process.
探讨仙灵骨葆（XLGB）对前交叉韧带横断（ACLT）诱导的大鼠骨关节炎模型软骨下骨和关节软骨的影响。
将24只3月龄雌性SD大鼠随机分为3组（n = 8）：假手术组（A组）、ACLT组（B组）和仙灵骨葆组（C组）。B组和C组通过ACLT制备骨关节炎模型，A组暴露前交叉韧带后缝合关节腔。4天后，C组给予仙灵骨葆250 mg/(kg·d)，A组和B组给予等量生理盐水。12周后，观察股骨髁大体形态，采用Mankin评分系统对软骨退变程度进行评分。进行基质金属蛋白酶-13（MMP-13）免疫染色，以研究仙灵骨葆对预防软骨基质丢失的作用。12周后对右股骨远端和胫骨近端软骨下骨进行骨密度（BMD）测量和骨组织形态计量分析。
股骨髁大体形态显示，12周后C组溃疡小于B组。C组Mankin评分和MMP-13免疫活性值均明显低于B组（P < 0.05）。B组软骨下骨BMD明显低于A组和C组（P < 0.05）。C组骨量明显高于B组（P < 0.05）。
口服仙灵骨葆（250 mg/kg每日）12周可预防ACLT后大鼠软骨退变，下调MMP-13和增加软骨下骨量可能参与此过程。
